glp 1 cardiovascular risk reduction How do GLP-1 RAs and dual agonists impact residual risk? Watch this on-demand R3i webinar featuring Prof. Michel Hermans and Prof. Peter Libby. The webinar reviews evidence from major CVOTs and GLP-1 and GIP–GLP-1 therapies benefits
Pay in 4 interest-free payments of $6.38 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 22 - Nov 27
























